Next Article in Journal
The Influence of Vaginal Native Tissue Repair (VNTR) on Various Aspects of Quality of Life in Women with Symptomatic Pelvic Organ Prolapse—A Prospective Cohort Study
Previous Article in Journal
Prevalence of Coronary Artery Calcification on Pre-Atrial Fibrillation Ablation CT Pulmonary Venograms and its Impact on Selection for Statin Therapy
Open AccessArticle

Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study

1
Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, LA 70115, USA
2
Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, LA 70121, USA
3
STATinMED Research, Ann Arbor, MI 48108, USA
4
Bristol-Myers Squibb Company, Lawrenceville, NJ 08648, USA
5
Pfizer, Inc., Groton, CT 06340, USA
6
Pfizer, Inc., New York, NY 10017, USA
7
University of North Carolina, Chapel Hill, NC 27599, USA
8
New York City College of Technology, City University of New York, New York, NY 11201, USA
9
Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool L69 3BX, UK
10
Liverpool Heart & Chest Hospital, Liverpool L14 3PE, UK
11
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 1633; https://doi.org/10.3390/jcm9061633
Received: 10 April 2020 / Revised: 22 May 2020 / Accepted: 27 May 2020 / Published: 28 May 2020
(This article belongs to the Section Cardiology)
This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with obesity prescribed warfarin or non-vitamin K antagonist oral anticoagulants (NOACs) in order to inform clinical decision making. A retrospective observational study was conducted among NVAF patients who were obese and initiated apixaban, dabigatran, rivaroxaban, or warfarin from 1 January 2013–30 September 2015, with data pooled from CMS Medicare and four US commercial claims databases. Propensity score matching was completed between NOACs and against warfarin in each database, and the results were pooled. Cox models were used to evaluate the risks of stroke/SE and MB. A total of 88,461 patients with obesity were included in the study. Apixaban and rivaroxaban were associated with a lower risk of stroke/SE vs. warfarin (HR: 0.63, 95% CI: 0.49–0.82 and HR: 0.84, 95% CI: 0.72–0.98). Dabigatran was associated with a similar risk of stroke/SE compared to warfarin. Compared with warfarin, apixaban and dabigatran had a lower risk of MB (HR: 0.54, 95% CI: 0.49–0.61 and HR: 0.75, 95% CI: 0.63–0.91). Rivaroxaban was associated with a similar risk of MB compared to warfarin. In this high-risk population with obesity, NOACs had a varying risk of stroke/SE and MB vs. warfarin. View Full-Text
Keywords: stroke; coagulation; outcomes; cardiovascular disease stroke; coagulation; outcomes; cardiovascular disease
Show Figures

Figure 1

MDPI and ACS Style

Deitelzweig, S.; Keshishian, A.; Kang, A.; Dhamane, A.D.; Luo, X.; Li, X.; Balachander, N.; Rosenblatt, L.; Mardekian, J.; Pan, X.; Di Fusco, M.; Garcia Reeves, A.B.; Yuce, H.; Lip, G.Y.H. Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. J. Clin. Med. 2020, 9, 1633.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop